Deng Yudi, Zhang Xudong, Shen Haibin, He Qiangnan, Wu Zijian, Liao Wenzhen, Yuan Miaomiao
The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Guangdong Provincial Key Laboratory of Tropical Disease Research, Department of Nutrition and Food Hygiene, School of Public Health, Southern Medical University, Guangzhou, China.
Front Bioeng Biotechnol. 2020 Jan 31;7:489. doi: 10.3389/fbioe.2019.00489. eCollection 2019.
Cardiovascular diseases (CVDs) have become a serious threat to human life and health. Though many drugs acting via different mechanism of action are available in the market as conventional formulations for the treatment of CVDs, they are still far from satisfactory due to poor water solubility, low biological efficacy, non-targeting, and drug resistance. Nano-drug delivery systems (NDDSs) provide a new drug delivery method for the treatment of CVDs with the development of nanotechnology, demonstrating great advantages in solving the above problems. Nevertheless, there are some problems about NDDSs need to be addressed, such as cytotoxicity. In this review, the types and targeting strategies of NDDSs were summarized, and the new research progress in the diagnosis and therapy of CVDs in recent years was reviewed. Future prospective for nano-carriers in drug delivery for CVDs includes gene therapy, in order to provide more ideas for the improvement of cardiovascular drugs. In addition, its safety was also discussed in the review.
心血管疾病(CVDs)已成为对人类生命和健康的严重威胁。尽管市场上有许多通过不同作用机制起作用的药物作为治疗CVDs的传统制剂,但由于水溶性差、生物疗效低、非靶向性和耐药性,它们仍然远不能令人满意。随着纳米技术的发展,纳米药物递送系统(NDDSs)为CVDs的治疗提供了一种新的药物递送方法,在解决上述问题方面显示出巨大优势。然而,NDDSs存在一些需要解决的问题,如细胞毒性。在这篇综述中,总结了NDDSs的类型和靶向策略,并综述了近年来CVDs诊断和治疗的新研究进展。纳米载体在CVDs药物递送中的未来前景包括基因治疗,以便为改进心血管药物提供更多思路。此外,综述中还讨论了其安全性。